Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2002 Oct;57(10):841–846. doi: 10.1136/thorax.57.10.841

Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

R Suri 1, R Grieve 1, C Normand 1, C Metcalfe 1, S Thompson 1, C Wallis 1, A Bush 1
PMCID: PMC1746194  PMID: 12324668

Abstract

Background: Daily recombinant human deoxyribonuclease (rhDNase) is an established but expensive treatment in cystic fibrosis (CF). An alternative lower cost therapy is hypertonic saline (HS), which has been shown to improve lung function in short term studies. This study compares the costs and consequences of daily rhDNase with alternate day rhDNase and HS in children with CF.

Methods: In an open, randomised, crossover trial, 48 children with CF were allocated consecutively to 12 weeks of once daily 2.5 mg rhDNase, alternate day 2.5 mg rhDNase, and twice daily 5 ml 7% HS. Outcomes assessed included forced expiratory volume in 1 second (FEV1) and quality of life. All healthcare resource use was prospectively recorded for each patient. Unit costs were collected and combined with resource use data to give the total health service costs per patient for each treatment strategy.

Results: Daily rhDNase resulted in a significantly greater increase in mean FEV1 than HS (8%, 95% CI 2 to 14) but there was no significant difference in FEV1 between daily and alternate day rhDNase (2%, 95% CI –4 to 9). Over a 12 week period the mean incremental costs of daily rhDNase compared with HS was £1409 (95% CI £440 to £2318), and the incremental cost of using daily rather than alternate day rhDNase was £513 (95% CI –£546 to £1510).

Conclusions: Daily rhDNase is more effective than 5 ml 7% HS twice daily delivered by jet nebuliser, but significantly increases healthcare costs. Administering rhDNase on an alternate day rather than a daily basis is as effective, with a potential for cost savings.

Full Text

The Full Text of this article is available as a PDF (140.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Briggs A. H., Gray A. M. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess. 1999;3(2):1–134. [PubMed] [Google Scholar]
  2. Christopher F., Chase D., Stein K., Milne R. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease. J Clin Pharm Ther. 1999 Dec;24(6):415–426. doi: 10.1046/j.1365-2710.1999.00245.x. [DOI] [PubMed] [Google Scholar]
  3. Davies J., Trindade M. T., Wallis C., Rosenthal M., Crawford O., Bush A. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol. 1997 Apr;23(4):243–248. doi: 10.1002/(sici)1099-0496(199704)23:4<243::aid-ppul1>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  4. Drummond M. F., Jefferson T. O. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996 Aug 3;313(7052):275–283. doi: 10.1136/bmj.313.7052.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eng P. A., Morton J., Douglass J. A., Riedler J., Wilson J., Robertson C. F. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol. 1996 Feb;21(2):77–83. doi: 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  6. FitzSimmons S. C. The changing epidemiology of cystic fibrosis. J Pediatr. 1993 Jan;122(1):1–9. doi: 10.1016/s0022-3476(05)83478-x. [DOI] [PubMed] [Google Scholar]
  7. Fuchs H. J., Borowitz D. S., Christiansen D. H., Morris E. M., Nash M. L., Ramsey B. W., Rosenstein B. J., Smith A. L., Wohl M. E. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8;331(10):637–642. doi: 10.1056/NEJM199409083311003. [DOI] [PubMed] [Google Scholar]
  8. Johnston K., Buxton M. J., Jones D. R., Fitzpatrick R. Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess. 1999;3(6):1–76. [PubMed] [Google Scholar]
  9. Menzin J., Oster G., Davies L., Drummond M. F., Greiner W., Lucioni C., Merot J. L., Rossi F., vd Schulenburg J. G., Souêtre E. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Int J Technol Assess Health Care. 1996 Winter;12(1):52–61. doi: 10.1017/s0266462300009387. [DOI] [PubMed] [Google Scholar]
  10. Ollendorf D. A., McGarry L. J., Watrous M. L., Oster G. Use of rhDNase therapy and costs of respiratory-related care in patients with cystic fibrosis. Ann Pharmacother. 2000 Mar;34(3):304–308. doi: 10.1345/aph.19159. [DOI] [PubMed] [Google Scholar]
  11. Orenstein D. M., Nixon P. A., Ross E. A., Kaplan R. M. The quality of well-being in cystic fibrosis. Chest. 1989 Feb;95(2):344–347. doi: 10.1378/chest.95.2.344. [DOI] [PubMed] [Google Scholar]
  12. Oster G., Huse D. M., Lacey M. J., Regan M. M., Fuchs H. J. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Ann Pharmacother. 1995 May;29(5):459–464. doi: 10.1177/106002809502900501. [DOI] [PubMed] [Google Scholar]
  13. Ramsey B. W., Astley S. J., Aitken M. L., Burke W., Colin A. A., Dorkin H. L., Eisenberg J. D., Gibson R. L., Harwood I. R., Schidlow D. V. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993 Jul;148(1):145–151. doi: 10.1164/ajrccm/148.1.145. [DOI] [PubMed] [Google Scholar]
  14. Ramsey B. W., Dorkin H. L. Consensus conference: practical applications of Pulmozyme. September 22, 1993. Pediatr Pulmonol. 1994 Jun;17(6):404–408. doi: 10.1002/ppul.1950170613. [DOI] [PubMed] [Google Scholar]
  15. Ranasinha C., Assoufi B., Shak S., Christiansen D., Fuchs H., Empey D., Geddes D., Hodson M. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993 Jul 24;342(8865):199–202. doi: 10.1016/0140-6736(93)92297-7. [DOI] [PubMed] [Google Scholar]
  16. Suri R., Metcalfe C., Lees B., Grieve R., Flather M., Normand C., Thompson S., Bush A., Wallis C. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet. 2001 Oct 20;358(9290):1316–1321. doi: 10.1016/S0140-6736(01)06412-1. [DOI] [PubMed] [Google Scholar]
  17. Thompson S. G., Barber J. A. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000 Apr 29;320(7243):1197–1200. doi: 10.1136/bmj.320.7243.1197. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES